Evidence map›Paper›PMID 38073575›Full record

ArticleAnnals of surgery2023

Nationwide Outcome after Pancreatoduodenectomy in Patients at very High Risk (ISGPS-D) for Postoperative Pancreatic Fistula.

Rutger T Theijse, Thomas F Stoop, Tessa E Hendriks, J Annelie Suurmeijer, F Jasmijn Smits, Bert A Bonsing, Daan J Lips, Eric Manusama, Erwin van der Harst, Gijs A Patijn and 17 more

Open access · hybridAbstract read
In one paragraph

Article in Annals of surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 13 institutions in 4 countries.

Rutger T TheijseAmsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
Thomas F StoopAmsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
Tessa E HendriksAmsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
J Annelie SuurmeijerAmsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
F Jasmijn SmitsDepartment of Surgery, Regional Academic Cancer Center Utrecht, University Medical Center Utrecht and St. Antonius Hospital Nieuwegein, Utrecht University, the Netherlands.
Bert A BonsingDepartment of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
Daan J LipsDepartment of Surgery, Medisch Spectrum Twente, Enschede, the Netherlands.
Eric ManusamaDepartment of Surgery, Medisch Centrum Leeuwarden, the Netherlands.
Erwin van der HarstDepartment of Surgery, Maasstad Hospital, Rotterdam, the Netherlands.
Gijs A PatijnDepartment of Surgery, Isala Clinics, Zwolle, the Netherlands.
Jan H WijsmanDepartment of Surgery, Amphia Hospital, Breda, the Netherlands.
Mark MeerdinkDepartment of Surgery, University Medical Center Groningen, Groningen, the Netherlands.
Marcel den DulkDepartment of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands.
Ronald van DamDepartment of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands.
Martijn W J StommelDepartment of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.
Kees van LaarhovenDepartment of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.
Roeland F de WildeDepartment of Surgery, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
Sebastiaan FestenDepartment of Surgery, OLVG Oost, Amsterdam, the Netherlands.
Werner A DraaismaDepartment of Surgery, Jeroen Bosch Hospital, 's Hertogenbosch, the Netherlands.
Koop BosschaDepartment of Surgery, Jeroen Bosch Hospital, 's Hertogenbosch, the Netherlands.
Casper H J van EijckDepartment of Surgery, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
Olivier R BuschAmsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
I Quintus MolenaarDepartment of Surgery, Regional Academic Cancer Center Utrecht, University Medical Center Utrecht and St. Antonius Hospital Nieuwegein, Utrecht University, the Netherlands.
Bas Groot KoerkampDepartment of Surgery, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
Hjalmar C van SantvoortDepartment of Surgery, Regional Academic Cancer Center Utrecht, University Medical Center Utrecht and St. Antonius Hospital Nieuwegein, Utrecht University, the Netherlands.
Marc G BesselinkAmsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
Dutch Pancreatic Cancer Group
Amsterdam University Medical Centers · NLUtrecht University · NLLeiden University Medical Center · NLErasmus MC Cancer Institute · NLRadboud University Nijmegen · NLAmphia Ziekenhuis · NLGGZ Oost Brabant · NLIsala · NLMaasstad Ziekenhuis · NLMedisch Centrum Leeuwarden · NLMedisch Spectrum Twente · NLTongling Nonferrous Metals Group Holding (China) · CNUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess nationwide surgical outcome after pancreatoduodenectomy (PD) in patients at very high risk for postoperative pancreatic fistula (POPF), categorized as ISGPS-D. SUMMARY BACKGROUND DATA: Morbidity and mortality after ISGPS-D PD is perceived so high that a recent randomized trial advocated prophylactic total pancreatectomy (TP) as alternative aiming to lower this risk. However, current outcomes of ISGPS-D PD remain unknown as large nationwide series are lacking.

methodsNationwide retrospective analysis including consecutive patients undergoing ISGPS-D PD (i.e., soft texture and pancreatic duct ≤3 mm), using the mandatory Dutch Pancreatic Cancer Audit (2014-2021). Primary outcome was in-hospital mortality and secondary outcomes included major morbidity (i.e., Clavien-Dindo grade ≥IIIa) and POPF (ISGPS grade B/C). The use of prophylactic TP to avoid POPF during the study period was assessed.

resultsOverall, 1402 patients were included. In-hospital mortality was 4.1% (n=57), which decreased to 3.7% (n=20/536) in the last 2 years. Major morbidity occurred in 642 patients (45.9%) and POPF in 410 (30.0%), which corresponded with failure to rescue in 8.9% (n=57/642). Patients with POPF had increased rates of major morbidity (88.0% vs. 28.3%; P<0.001) and mortality (6.3% vs. 3.5%; P=0.016), compared to patients without POPF. Among 190 patients undergoing TP, prophylactic TP to prevent POPF was performed in 4 (2.1%).

conclusionThis nationwide series found a 4.1% in-hospital mortality after ISGPS-D PD with 45.9% major morbidity, leaving little room for improvement through prophylactic TP. Nevertheless, given the outcomes in 30% of patients who develop POPF, future randomized trials should aim to prevent and mitigate POPF in this high-risk category.

Identifiers

PMID38073575
PMCPMC11723487
OpenAlexW4389571287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.